{"id":"sars-cov-2-inactivated-vaccine","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Injection site pain or swelling"},{"rate":"10–30","effect":"Fatigue"},{"rate":"10–25","effect":"Headache"},{"rate":"10–20","effect":"Myalgia"},{"rate":"5–15","effect":"Fever"},{"rate":"5–10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains chemically inactivated (killed) SARS-CoV-2 virions that cannot replicate. When administered, these viral particles trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize live virus upon exposure. This approach has been used successfully in other viral vaccines such as polio and influenza.","oneSentence":"An inactivated whole-virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting non-infectious viral particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:00.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 caused by SARS-CoV-2"}]},"trialDetails":[{"nctId":"NCT05765773","phase":"PHASE2","title":"An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2021-07-01","conditions":"Corona Virus Infection, Vaccine, COVID-19","enrollment":200},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06181656","phase":"","title":"Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-05","conditions":"Pneumococcal Vaccine, Esophageal Cancer, Lymphopenia","enrollment":80},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT06605625","phase":"","title":"Vaccine Responses in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-11-04","conditions":"Viral Vaccines","enrollment":250},{"nctId":"NCT06355232","phase":"PHASE1","title":"Covid-19 and Influenza Oral Vaccine Study","status":"RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2024-05-01","conditions":"covid19 Infection, Influenza, Human","enrollment":100},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT05716347","phase":"EARLY_PHASE1","title":"Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years","status":"TERMINATED","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2022-07-13","conditions":"COVID-19","enrollment":80},{"nctId":"NCT05727215","phase":"PHASE2","title":"Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2023-02-28","conditions":"COVID-19","enrollment":150},{"nctId":"NCT05525208","phase":"PHASE2","title":"Booster Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-09-01","conditions":"COVID-19","enrollment":696},{"nctId":"NCT06997653","phase":"PHASE2","title":"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women","status":"WITHDRAWN","sponsor":"Health Institutes of Turkey","startDate":"2024-01-01","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":""},{"nctId":"NCT05035238","phase":"PHASE2","title":"Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine(TURKOVAC) in Healthy Population of 18 and 64 Years of Age (Both Inclusive):a Randomized, Double-blind, Phase IIb Clinical Trial","status":"WITHDRAWN","sponsor":"Health Institutes of Turkey","startDate":"2021-10-01","conditions":"Covid19","enrollment":""},{"nctId":"NCT05043259","phase":"PHASE1, PHASE2","title":"Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-08-14","conditions":"COVID-19","enrollment":423},{"nctId":"NCT05204589","phase":"PHASE3","title":"Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-01-22","conditions":"COVID-19","enrollment":10285},{"nctId":"NCT05303584","phase":"PHASE4","title":"Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-04-23","conditions":"COVID-19","enrollment":362},{"nctId":"NCT05354024","phase":"PHASE2, PHASE3","title":"Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-02-28","conditions":"Coronavirus Infections, Healthy","enrollment":4400},{"nctId":"NCT05463419","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.","status":"COMPLETED","sponsor":"Yisheng Biopharma (Singapore) Pte. Ltd.","startDate":"2022-10-03","conditions":"Covid-19 Vaccine","enrollment":5860},{"nctId":"NCT05310084","phase":"PHASE3","title":"Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-04-20","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1134},{"nctId":"NCT05381350","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-06-01","conditions":"COVID-19","enrollment":1750},{"nctId":"NCT05230940","phase":"PHASE2","title":"Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-02-18","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":1},{"nctId":"NCT04582344","phase":"PHASE3","title":"Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-09-14","conditions":"COVID-19","enrollment":10214},{"nctId":"NCT05409300","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-25","conditions":"COVID-19, Vaccine Adverse Reaction, Sars-CoV-2 Infection","enrollment":200},{"nctId":"NCT05028361","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-10-04","conditions":"Quality of Life, Injection Site Reaction, Adverse Drug Event","enrollment":348},{"nctId":"NCT04942405","phase":"PHASE3","title":"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-06-21","conditions":"Covid19","enrollment":1290},{"nctId":"NCT05077176","phase":"PHASE3","title":"Phase 3 Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-10-08","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":4340},{"nctId":"NCT06282692","phase":"PHASE3","title":"INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-06-19","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":400},{"nctId":"NCT06272253","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-09-19","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":250},{"nctId":"NCT06259578","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2024-01-29","conditions":"COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease","enrollment":400},{"nctId":"NCT05308602","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years","status":"WITHDRAWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-04-01","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT05239975","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine","status":"WITHDRAWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-04-25","conditions":"COVID-19, SARS-CoV2 Infection","enrollment":""},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT05057182","phase":"PHASE4","title":"Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-10-18","conditions":"COVID 19 Vaccine","enrollment":300},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":"COVID-19 Vaccination","enrollment":400},{"nctId":"NCT04979949","phase":"PHASE2","title":"Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-07-12","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":222},{"nctId":"NCT05112913","phase":"PHASE4","title":"Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-27","conditions":"COVID-19","enrollment":2520},{"nctId":"NCT05831826","phase":"","title":"Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China","status":"UNKNOWN","sponsor":"Zhejiang Chinese Medical University","startDate":"2020-06-01","conditions":"COVID-19 Vaccines, Autoimmune Diseases","enrollment":1200},{"nctId":"NCT05137418","phase":"PHASE3","title":"Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-11-27","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04992260","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-09-10","conditions":"COVID-19","enrollment":11349},{"nctId":"NCT04470609","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2020-07-10","conditions":"COVID-19","enrollment":471},{"nctId":"NCT04412538","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2020-05-15","conditions":"COVID-19","enrollment":942},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04551547","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2020-10-31","conditions":"COVID-19","enrollment":552},{"nctId":"NCT05683600","phase":"PHASE3","title":"Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older","status":"TERMINATED","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-12-29","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT05664932","phase":"PHASE3","title":"Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-12-28","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT04911790","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-06-05","conditions":"COVID-19","enrollment":131650},{"nctId":"NCT04992208","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-07-24","conditions":"COVID-19","enrollment":31041},{"nctId":"NCT05254236","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-02-10","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04884685","phase":"PHASE2","title":"Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-05-03","conditions":"COVID-19","enrollment":500},{"nctId":"NCT05205096","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-11-10","conditions":"COVID-19","enrollment":480},{"nctId":"NCT04956224","phase":"PHASE3","title":"Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-08-09","conditions":"SARS-CoV-2 Virus Infection","enrollment":306},{"nctId":"NCT04993209","phase":"PHASE1","title":"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-07-09","conditions":"Coronavirus Infections, Healthy","enrollment":320},{"nctId":"NCT05952505","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines","status":"UNKNOWN","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","startDate":"2023-08","conditions":"SARS-CoV-2 Infection, Varicella, Measles","enrollment":540},{"nctId":"NCT05609045","phase":"PHASE1","title":"A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster","status":"WITHDRAWN","sponsor":"Wuhan Rhegen Biotechnology Co., Ltd.","startDate":"2023-06","conditions":"COVID-19 Pandemic","enrollment":""},{"nctId":"NCT05928455","phase":"EARLY_PHASE1","title":"The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-05-14","conditions":"COVID-19, Vaccine Reaction","enrollment":120},{"nctId":"NCT05928468","phase":"EARLY_PHASE1","title":"The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2023-04-25","conditions":"COVID-19","enrollment":210},{"nctId":"NCT05918939","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-09-05","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":350},{"nctId":"NCT04863638","phase":"PHASE4","title":"A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2021-04-29","conditions":"Covid19","enrollment":4400},{"nctId":"NCT04510207","phase":"PHASE3","title":"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-07-16","conditions":"COVID-19","enrollment":44101},{"nctId":"NCT04917523","phase":"PHASE3","title":"Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-07-02","conditions":"COVID-19 Pneumonia, COVID-19","enrollment":1800},{"nctId":"NCT05226429","phase":"PHASE1, PHASE2","title":"UNAIR Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-02-08","conditions":"COVID-19 Pandemic, Vaccine Reaction","enrollment":495},{"nctId":"NCT05895110","phase":"NA","title":"To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-04-29","conditions":"COVID-19","enrollment":240},{"nctId":"NCT05364242","phase":"PHASE2, PHASE3","title":"VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2022-05-09","conditions":"SARS-CoV-2 Infection","enrollment":178},{"nctId":"NCT04612972","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2020-09-09","conditions":"COVID-19","enrollment":12000},{"nctId":"NCT05323435","phase":"PHASE2","title":"Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)","status":"COMPLETED","sponsor":"Jiangsu Rec-Biotechnology Co., Ltd.","startDate":"2022-05-30","conditions":"COVID-19","enrollment":300},{"nctId":"NCT05096832","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-03","conditions":"COVID-19 Pandemic","enrollment":10381},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360},{"nctId":"NCT04866069","phase":"PHASE1","title":"Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults","status":"TERMINATED","sponsor":"Osman ERGANIS, PhD, Prof","startDate":"2021-04-25","conditions":"Covid19","enrollment":50},{"nctId":"NCT05580159","phase":"PHASE3","title":"New Generation mRNA Booster Vaccine Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10","conditions":"Immunogenicity, Efficacy, Safety","enrollment":2000},{"nctId":"NCT05323461","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-05-30","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":1800},{"nctId":"NCT05258669","phase":"PHASE2, PHASE3","title":"Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults","status":"UNKNOWN","sponsor":"Ocugen","startDate":"2022-02-20","conditions":"COVID-19","enrollment":400},{"nctId":"NCT04864561","phase":"PHASE3","title":"COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-04-26","conditions":"SARS-CoV-2 Virus Infection","enrollment":4034},{"nctId":"NCT05715918","phase":"PHASE3","title":"Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive\"","status":"UNKNOWN","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2022-04-01","conditions":"Vaccine","enrollment":300},{"nctId":"NCT05745545","phase":"NA","title":"Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-01-04","conditions":"SARS-CoV-2","enrollment":3200},{"nctId":"NCT05228613","phase":"PHASE1","title":"Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-02-16","conditions":"COVID-19","enrollment":175},{"nctId":"NCT05115019","phase":"PHASE2, PHASE3","title":"A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19)","status":"WITHDRAWN","sponsor":"PT. Innovative Pharma Solutions","startDate":"2021-12","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05545683","phase":"PHASE3","title":"Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination","status":"WITHDRAWN","sponsor":"Centro de Estudios en Infectogía Pediatrica","startDate":"2022-12-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05407142","phase":"PHASE3","title":"An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)","status":"UNKNOWN","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2021-07-07","conditions":"Coronavirus Infections, Vaccine","enrollment":29000},{"nctId":"NCT05156632","phase":"PHASE3","title":"Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2023-02-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05428592","phase":"PHASE3","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-04","conditions":"SARS-CoV-2","enrollment":1100},{"nctId":"NCT04651790","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-11-27","conditions":"Covid19, Vaccines","enrollment":2300},{"nctId":"NCT04903184","phase":"PHASE2","title":"Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers","status":"COMPLETED","sponsor":"RUTI Immunotherapeutics S.L.","startDate":"2021-01-06","conditions":"Covid-19","enrollment":251},{"nctId":"NCT05686161","phase":"PHASE3","title":"mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10-19","conditions":"Immunogenicity, Safety, Efficacy","enrollment":600},{"nctId":"NCT05367895","phase":"","title":"Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-07-30","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05680896","phase":"","title":"SARS-CoV-2 Infection Among Healthcare Workers","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-02-01","conditions":"COVID-19","enrollment":600},{"nctId":"NCT05668065","phase":"PHASE3","title":"Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines","status":"COMPLETED","sponsor":"Institut Pasteur de Tunis","startDate":"2021-11-22","conditions":"COVID-19","enrollment":199},{"nctId":"NCT05518760","phase":"","title":"COVID-19 Effectiveness Study in the Philippines","status":"UNKNOWN","sponsor":"University of the Philippines","startDate":"2022-11-09","conditions":"COVID-19, Vaccine Effectiveness Against COVID-19, Hospitalized COVID-19","enrollment":3000},{"nctId":"NCT05298644","phase":"PHASE2, PHASE3","title":"COVID-19 Paediatric VLA2001-321 Study","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2022-10-01","conditions":"SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT05602558","phase":"PHASE2, PHASE3","title":"The Phase Ⅱ/Ⅲ Trial of LYB001","status":"UNKNOWN","sponsor":"Yantai Patronus Biotech Co., Ltd.","startDate":"2022-12","conditions":"COVID-19","enrollment":18000},{"nctId":"NCT05599802","phase":"PHASE1","title":"Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-02","conditions":"SARS-CoV-2","enrollment":144},{"nctId":"NCT05492643","phase":"NA","title":"The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2022-08-13","conditions":"SARS-CoV-2, Safety, Immunotoxicity","enrollment":1000},{"nctId":"NCT05568693","phase":"NA","title":"Sequential Enhanced Safety Study of a Novel Coronavirus Messenger RNA (mRNA) Vaccine in Adults Aged 18 Years and Older.","status":"UNKNOWN","sponsor":"Yu Qin","startDate":"2022-09-21","conditions":"Corona Virus Disease 2019(COVID-19)","enrollment":800},{"nctId":"NCT05541289","phase":"","title":"Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older","status":"NO_LONGER_AVAILABLE","sponsor":"Ocugen","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05109559","phase":"PHASE1, PHASE2","title":"Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-12-20","conditions":"SARS-CoV-2 Infection","enrollment":690},{"nctId":"NCT05126550","phase":"","title":"The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine","status":"UNKNOWN","sponsor":"PT. Kimia Farma (Persero) Tbk","startDate":"2021-11-13","conditions":"COVID-19","enrollment":435},{"nctId":"NCT05172193","phase":"PHASE2","title":"Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)","status":"UNKNOWN","sponsor":"PT. Kimia Farma (Persero) Tbk","startDate":"2021-12-31","conditions":"COVID-19","enrollment":600},{"nctId":"NCT05508477","phase":"PHASE3","title":"UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-06-28","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":4005},{"nctId":"NCT04974164","phase":"","title":"Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-08-17","conditions":"COVID-19","enrollment":1400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CoronaVac","Coronavac"],"phase":"marketed","status":"active","brandName":"SARS-CoV-2 Inactivated Vaccine","genericName":"SARS-CoV-2 Inactivated Vaccine","companyName":"PT Bio Farma","companyId":"pt-bio-farma","modality":"Biologic","firstApprovalDate":"","aiSummary":"An inactivated whole-virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting non-infectious viral particles. Used for Prevention of COVID-19 caused by SARS-CoV-2.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}